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Abstract
Several studies report autoantibody signatures in cancer. The majority of these studies analyzed adult tumors and
compared the seroreactivity pattern of tumor patients with the pattern in healthy controls. Here, we compared the
autoimmune response in patients with neuroblastoma and patients with Wilms tumor representing two different childhood
tumors. We were able to differentiate untreated neuroblastoma patients from untreated Wilms tumor patients with an
accuracy of 86.8%, a sensitivity of 87.0% and a specificity of 86.7%. The separation of treated neuroblastoma patients from
treated Wilms tumor patients’ yielded comparable results with an accuracy of 83.8%. We furthermore identified the antigens
that contribute most to the differentiation between both tumor types. The analysis of these antigens revealed that
neuroblastoma was considerably more immunogenic than Wilms tumor. The reported antigens have not been found to be
relevant for comparative analyses between other tumors and controls. In summary, neuroblastoma appears as a highly
immunogenic tumor as demonstrated by the extended number of antigens that separate this tumor from Wilms tumor.
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Introduction
Neuroblastoma is the most common childhood cancer occur-
ring in about 7% of childhood cancers, and has an incidence of
about 10 per million children per year in Europe [1].
Neuroblastoma is a clinically very heterogenous tumor that was
originally classified into six different stages according to the INRG
(I, IIA, IIB, III, IV, IVS) by the postsurgical INSS [2]. A new
pretreatment staging system, the INRG staging system (INRGSS),
was developed in 2009 [3]. By now, stage, age, histologic category,
grade of tumor differentiation, MYCN status, 11q aberration and
ploidy are the most important parameters for pretreatment risk
classification [4]. The most prominent genetic marker is the
MYCN-amplification that has been associated with a worse
prognosis [5,6]. MYCN that is located on 2p23-24 encodes
proteins deregulating cell growth and proliferation upon amplifi-
cation. Further amplifications in neuroblastoma include the
MDM2 gene on 12q13 and the MYCL gene at 1p32 [7,8].
Furthermore, deletions and loss of heterozygosity (LOH) of
chromosome 1p seem to be significant for prognosis [9–11].
Urinary homovanillic acid and vanillylmandelic acid as
metabolites of catecholamines [12] have been employed in mass
screenings for neuroblastoma in Japan, North America and
Europe [13–16]. These screenings increased the incidence in
infants without decreasing the incidence of unfavorable advanced-
stage disease in older children. Overall, mass screenings did not
reduce the mortality for neuroblastoma [16,17]. As of now, the
effectiveness of mass screening is controversially discussed [18–21].
A specific diagnostic challenge is the differentiation between
neuroblastoma and Wilms tumor (WT) as the most common renal
childhood tumor [22]. There is evidence that preoperative
imaging for differentiation between Wilms tumors and Non-
Wilms tumors is not in 100% accurate [23,24]. In Europe Wilms
tumor patients are treated without histology on the basis of their
characteristic radiological features alone according to the Societe´
Internationale d’Oncologie Pe´diatrique (SIOP) protocols. Char-
acteristic autoantibody signatures may be useful to confirm the
radiological discrimination between the suspected Wilms tumor
and e.g. neuroblastoma. In the US all WT patients undergo
histological confirmation and autoantibody signatures are there-
fore not needed for differential diagnosis (Children’s Oncology
Group) [25,26].
As of now, most classifications with autoantibodies were
designed to separating adult cancer patients from healthy controls
[27–30]. The accuracy of such separations yielded average values
of 80–95%. There are only few attempts to define pattern of
immunogenic antigens that allow classifications between different
diseases. A classification of glioma sera versus sera of patients with
other intracranial tumor yielded an accuracy of 88.0%. A
classification between glioma sera and sera of patients with non-
tumor brain pathologies yielded an accuracy of 87.8% [31]. Lung
cancer and patients with non-tumor lung pathologies were
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separated with an accuracy of 88.5% [28]. As of now, there have
not been any reports on autoantigen signatures in renal childhood
tumors or neuroblastoma.
In this work, we investigated to what extend the humoral
immune response can be exploited to arrive at new biological
markers that may be useful for children with an abdominal mass.
Specifically, we ask if and how many autoantibodies can be found
in children with neuroblastoma, if an autoantibody signature can
be deduced for neuroblastoma and if such a signature allows
differentiation between neuroblastoma and Wilms tumor. This
study is aimed to lay the ground to further exploit autoantibody
signatures for diagnostic purposes of patients with neuroblastoma.
Results
Search for immunogenic antigens of patients with Wilms
tumors or neuroblastomas
To identify immunogenic clones that differentiate Wilms tumor
patients from patients with neuroblastoma we used an array based
approach as previously described [29,32]. The array encompassed
1,827 immunogenic clones including 509 human in-frame
peptides and 1318 out-of-frame sequences. While in-frame clones
are transcribed in the correct reading frame, out of frame clones
may have an amino-acid sequence other than the natural antigen.
Each of the clones expressed a recombinant protein that was
previously shown to react with autoantibodies of human sera.
In this multicenter study we screened the arrays with sera of
neuroblastoma patients andWilms tumor patients. The reactivity of
serum autoantibodies against the E. coli expressed clones was
measured by an automated image analysis system. We discounted
clones that yielded read-out intensity values below 50. After
eliminating these clones we obtained 1520 reactive clones including
422 in-frame clones. To differentiate between neuroblastoma and
Wilms tumor patients, we separately analyzed patients prior to
treatment and after treatment. First, we compared 30 sera of
untreated neuroblastoma patients and 53 sera of untreated Wilms
tumor patients. For both diseases, the majority of the clones reacted
with approximately 50% of the sera. Only a smaller number of
clones reacted with nearly all sera tested. Likewise, a smaller
number reacted with few sera. Table 1 shows the distribution of the
frequency of reactivities for all clones. Overall, we found for both
Wilms tumor patients and neuroblastoma patients an extended and
comparably high number of serum antibodies that react with the
recombinant antigens.
Identification of specific clones that contributed most to
a separation between patients with neuroblastoma or
Wilms tumors
Beside the numerical similarity we frequently found the same
antigens that were reactive against sera of neuroblastoma patients
and sera of Wilms tumor patients. As an example we chose clones
that were reactive with over 90% of the sera. We found 14 in
frame clones that were reactive with more than 90% of sera from
untreated neuroblastoma patients and eight in frame clones that
were reactive with more than 90% of sera from untreated Wilms
tumor patients. Five of these clones were reactive in over 90% of
sera of both patients groups. Clones that were reactive with over
90% of either Wilms tumor or neuroblastoma patients, were each
also reactive with 68.5–90% of sera of the other patient group
(Tables 1 and 2).
Based on the frequencies of seroreactivities we set out to identify
specific clones that contributed most to a separation between
neuroblastoma and Wilms tumors. To this extent we computed
the AUC (area under the curve) value for each clone. Most of
clones showed AUC values from 0.3 to 0.7 (Table 3). Clones with
an AUC value greater than 0.7 or smaller than 0.3 were
considered informative for the separation. Clones with AUC
values smaller than 0.3 were more reactive with neuroblastoma
sera and clones with AUC values greater than 0.7 were more
reactive with Wilms tumor sera. For our analysis we concentrated
on in-frame clones that encode known proteins. For out-of-frame
clones, we cannot readily deduce the according proteins. Notably,
we found a characteristic signature for neuroblastoma versus
Wilms tumor only focusing on in-frame clones. In total, we
obtained two in frame clones with AUC values greater than 0.7
and 16 in frame clones with AUC values smaller than 0.3
including two clones with values even smaller than 0.2. Both of the
latter clones encoded the protein exostosin-2 (Table 4). The first
exostosin-2 encoding clone showed an AUC value of 0.189 (p-
value of 0.001) and the second clone an AUC value of 0.200 (p-
value 0.0017). The seroreactivity of the first clone was 2.25 fold
higher with neuroblastoma sera as compared to Wilms tumor sera
and the second clone was 3.24 fold higher with neuroblastoma
sera. A third clone encoding exostosin-2 was also informative with
Table 1. Number of reactive clones with sera of untreated neuroblastoma patients (NBs) and sera of untreated Wilms tumor
patients (WTs).
Sera of untreated WTs Sera of untreated NBs Sera of treated WTs Sera of treated NBs
% all clones in frame all clones in frame all clones in frame all clones in frame
0.00–10.00 27 9 47 12 11 6 28 8
10.01–20.00 69 29 111 29 88 25 114 34
20.01–30.00 143 53 137 36 131 53 143 37
30.01–40.00 182 71 202 51 215 74 168 49
40.01–50.00 203 53 213 68 186 62 197 53
50.01–60.00 222 56 200 63 277 76 226 64
60.01–70.00 225 69 213 54 194 41 228 70
70.01–80.00 221 44 193 59 223 52 197 55
80.01–90.00 156 28 132 35 121 24 151 39
90.01–100.00 71 8 71 14 73 8 67 12
doi:10.1371/journal.pone.0028951.t001
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an AUC value of 0.269. This clone was 1.9 fold more reactive in
neuroblastoma sera. Table 4 provides an overview of all reactive
clones informative for the separation between neuroblastoma
and Wilms tumor sera. We did not explore all 16 clones, because
we concentrated on the clones with the most significant AUC
value. These clones differed the most in reaction frequency
between sera from neuroblastoma patients and sera from Wilms
tumor patients. In general, we found that informative clones are
more frequently reactive with sera of untreated neuroblastoma
patients than with sera of untreated Wilms tumor patients
indicating that the seroreactivity found in neuroblastoma patients
contribute most to the difference in the antigen profile of these
diseases.
Influence of treatment on the spectrum of clones that
contributed most to a separation between
neuroblastoma and Wilms tumors
Next we asked whether the treatment influenced the difference
between the antigen profiles of neuroblastoma and Wilms tumors.
To this end, we analyzed 30 sera of treated neuroblastoma
patients, and 35 sera of treated Wilms tumor patients. Like for
the untreated patients, we found that both treated Wilms tumor
patients and treated neuroblastoma patients show a comparably
high number of reactive serum antibodies. Likewise, two clones
that were frequently reactive with untreated Wilms tumor sera
were also frequently reactive with untreated neuroblastoma sera
and vice versa. Most of clones that were reactive with over 90%
of either treated Wilms tumor or treated neuroblastoma patients,
were each also reactive with high percentage of sera of the other
patient group (Table 2). Only one clone that was frequently
reactive in sera from treated neuroblastoma patients (0.933) was
much less reactive in sera of treated Wilms tumor patients (0.429)
(Table 2 highlighted in yellow). This clone encodes the amyloid
beta A4 precursor protein-binding family B member 1. AUC
analysis revealed one in frame clone with a value greater than 0.7
and 29 in frame clones with values smaller than 0.3 including
three clones with values smaller than 0.2. These three clones
encoded ELAV-like protein 4, Microtubule-associated proteins
1A/1B light chain 3A precursor and amyloid beta A4 precursor
protein-binding family B member 1, respectively (Table 5). As for
Table 2. Frequency of clones that were highly reactive in Wilms tumor (WTs) /neuroblastoma patients (NBs).
frequency frequency
sera of sera of sera of sera of
clone untreated WTs untreated NBs clone treated WTs treated NBs
MPMGp800I14577 0,944 0.9 MPMGp800M16569 0,943 0,700
MPMGp800E17587 0,925 0.7 MPMGp800G07549 0,943 0,900
MPMGp800F10584 0,907 0.9 MPMGp800P23525 0,914 0,667
MPMGp800M18529 0,815 1,000 MPMGp800M03509 0,914 0,786
MPMGp800J02545 0,815 1,000 MPMGp800M18529 0,914 0,733
MPMGp800C11538 0,796 0,967 MPMGp800G09554 0,914 0,900
MPMGp800I19519 0,870 0,967 MPMGp800J02545 0,857 0,967
MPMGp800F09528 0,852 0,933 MPMGp800B14594 0,743 0,967
MPMGp800G09554 0,815 0,933 MPMGp800G24535 0,743 0,967
MPMGp800I07558 0,796 0,933 MPMGp800M08584 0,857 0,933
MPMGp800M16569 0,685 0,933 MPMGp800B12523 0,714 0,933
MPMGp800B12523 0,833 0,933 MPMGp800L20578 0,857 0,933
MPMGp800G03526 0,600 0,933
MPMGp800H19569 0,800 0,933
MPMGp800K08584 0,600 0,933
MPMGp800I08563 0,429 0,933
Clones reactive with either more than 90% of sera from untreated Wilms tumor patients or sera from untreated neuroblastoma patients and either of sera from treated
Wilms tumor patients or sera from treated neuroblastoma patients (bold) and the appropriate frequency. Only one clone (italics) strongly differs in reaction frequency
between both groups analyzed. Clones are ordered by frequency.
doi:10.1371/journal.pone.0028951.t002
Table 3. Distribution of AUC values for the classification of
untreated Wilms tumor patients (WTs) vs. untreated
neuroblastoma patients (NBs) and treated Wilms tumor
patients (WTs) vs. treated neuroblastoma patients (NBs).
untreated NBs vs. treated NBs vs. treated
AUC value untreated WTs WTs
all clones in frame all clones in frame
0.9–1.0 0 0 0 0
0.8–0.9 4 0 0 0
0.7–0.8 55 2 16 1
0.6–0.7 290 44 201 36
0.5–0.6 495 121 494 108
0.4–0.5 439 135 488 147
0.3–0.4 208 102 256 98
0.2–0.3 26 16 55 29
0.1–0.2 2 2 9 3
0.0–0.1 0 0 0 0
doi:10.1371/journal.pone.0028951.t003
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the untreated patients, the seroreactivity found in treated
neuroblastoma patients contributed most to the difference
between the antigen profile of neuroblastoma and Wilms tumor
patients. Notably among the clones informative for the treated
patients was again a clone encoding exostosin-2 (AUC value
0.290). The seroreactivity of this clone was 2.5 fold higher with
sera of treated neuroblastoma patients as compared to sera of
treated Wilms tumor patients. Thus, an increased seroreactivity
for exostosin-2 was found in neuroblastoma patients both prior
and after treatment.
Accuracy of the separation between untreated Wilms
tumor patients versus untreated neuroblastoma patients
and between treated Wilms tumor patients versus
treated neuroblastoma patients
Besides the search for specific reactive antigens, we asked if and
to what extend an autoantibody signature based on the identified
in-frame antigens allows separation of both, untreated Wilms
tumor patients versus untreated neuroblastoma patients and
treated Wilms tumor patients versus treated neuroblastoma
patients. For the separation of untreated Wilms tumor patients
versus untreated neuroblastoma patients, we obtained an
accuracy of 0.868 (95% Confidence Intervals (CI): [0.853–
0.883]), a sensitivity of 0.870 (95% CI: [0.853–0.887]) and a
specificity of 0.867 (95% CI: [0.843–0.891]. For this classifica-
tion, we obtained a positive predictive value of 0.867, a negative
predictive value of 0.870, a positive likelihood of 6.525 and a
negative likelihood of 0.150. Comparable results were obtained
for the classification between treated neuroblastoma and treated
Wilms tumor patients. For this separation we found an accuracy
of 0.838 (95% CI: [0.827–0.849]), a sensitivity of 0.817 (95% CI:
[0.802–0.831]) and a specificity of 0.860 (95% CI: [0.843–0.877])
with a positive predictive value of 0.854, a negative predictive
value of 0.824, a positive likelihood of 5.833 and a negative
likelihood of 0.213. In summary, we found specific autoantibody
signatures both for Wilms tumor and neuroblastoma. The
classification accuracy was similar both prior and after treatment.
The specific autoantigens that contributed to the classification
were at least in part different prior and after chemotherapy
(Table 4 und 5). But we showed that the treatment changes the
autoantibody profiles, respectively.
Table 4. Antigens with a significant AUC value for the
classification of untreated Wilms tumor patients vs. untreated
neuroblastoma patients.
Antigen AUC
.0.7
Amyloid beta A4 precursor protein-binding family B member 1 0,735
Nonhistone chromosomal protein HMG-14 0,709
,0.3
Exostosin-2 0,189
Exostosin-2 0,200
Glial fibrillary acidic protein 0,227
GRIP1 associated protein 1 0,244
ELAV-like protein 3 0,248
Secretogranin III 0,268
Exostosin-2 0,269
splicing factor proline/glutamine rich 0,271
Vimentin 0,272
Splicing factor proline/glutamine rich 0,278
Eukaryotic translation initiation factor 1 0,280
Peptidyl-prolyl cis-trans isomerase E 0,291
B-cell CLL/lymphoma 11A isoform 3 0,296
Poly(A) binding protein cytoplasmic 1 0,296
Protein NDRG1 0,298
RNA binding motif protein 6 0,298
The three most informative antigens (bold) and the antigens informative prior
to and after chemotherapy (italics) are shown.
doi:10.1371/journal.pone.0028951.t004
Table 5. Antigens with a significant AUC value for the
classification of treated Wilms tumor patients vs. treated
neuroblastoma patients.
Antigen AUC
.0.7
hairy and enhancer of split 5 0,702
,0.3
ELAV-like protein 4 0,159
Microtubule-associated proteins 1A/1B light chain 3A
precursor
0,165
Amyloid beta A4 precursor protein-binding 0,175
FK506-binding protein 3 0,204
Protein flightless-1 homolog 0,213
Pyruvate kinase isozymes M1/M2 0,216
Poly(A) binding protein cytoplasmic 1 0,235
STIP1 homology and U-box containing protein 1 0,237
40S ribosomal protein S8 0,240
40S ribosomal protein S6 0,245
8D6 antigen 0,246
Amyloid beta A4 precursor protein-binding family B member 1 0,257
60S ribosomal protein L8 0,267
Microtubule-associated protein 2 isoform 1 0,268
Metastasis associated protein 0,269
Minichromosome maintenance complex component 3 0,270
Ribosomal protein L37 0,270
Calsyntenin-1 precursor 0,272
Amyloid beta A4 precursor protein-binding family B member 1 0,273
Podocalyxin-like 2 0,276
Nonhomologous end-joining factor 1 0,276
Ribosomal protein S4 X-linked X isoform 0,277
Nuclear prelamin A recognition factor isoform c 0,279
Ribosomal L1 domain containing 1 0,283
STIP1 homology and U-box containing protein 1 0,283
Bromodomain-containing protein 7 0,285
40S ribosomal protein S6 0,287
Exostosin-2 0,290
Alveolar soft part sarcoma chromosome region 0,295
Sorbin and SH3 domain containing 2 isoform 2 0,297
Nuclease sensitive element binding protein 1 0,299
The three most informative antigens (bold) and the antigens informative both
prior to and after chemotherapy (italics) are shown.
doi:10.1371/journal.pone.0028951.t005
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Discussion
Neuroblastoma and Wilms tumors are the most important
abdominal tumors in small children. As they are situated nearby in
the abdomen imaging studies are not able to distinguish them in all
cases. Catecholamines are not always elevated in neuroblastoma
and MIBG scanning is done with a radioactive substance.
Diagnostic tools using radioactivity should always be avoided in
small children, if possible. A good marker to discriminate all cases
of Wilms tumor from neuroblastoma is not available, yet. It has
also been shown by Hero et al. [24], that in few instances wrong
treatment is given to some children with neuroblastoma, as their
tumors were considered as nephroblastoma based on imaging
studies. Therefore better biomarkers are needed. Our analysis
shows that both neuroblastoma and Wilms tumor patients have
numerous serum autoantibodies.
Highly informative for the classification of neuroblastoma versus
Wilms tumor was the ELAV-like protein 4 (ELAVL4) that is
implicated in neuronal differentiation and has been associated
with Parkinson’s disease [33], the Microtubule-associated proteins
(MAP) 1A/1B light chain 3A precursor that are microtubule-
associated and mediate the interactions between cytoskeleton and
microtubules [34], Amyloid beta A4 precursor protein-binding
family B member 1 (APBB1) that plays a role in controlling
neurogenesis of GnRH-1 neurons [35].
Furthermore, among the informative antigens was exostosin-2
(EXT2) antigen that was most informative for the separation of
untreated neuroblastoma patients from untreated Wilms tumor
patients as determined by the AUC value. Likewise EXT2 was
informative for the separation between treated neuroblastoma and
treated Wilms tumor patients. In both comparisons the EXT2
seroreactivity was increased in frequency in neuroblastoma
patients as compared to Wilms tumor patients. An autoantibody
response against EXT2 has not been reported previously for other
adult tumors according to Immunome Database (http://ludwig-
sun5.unil.ch/CancerImmunomeDB/, last accessed in April 2011).
The EXT2 gene encodes a glycosyltransferase that is involved in
the heparan sulfate biosynthesis [36–38]. Loss of heterozygosity
was described for multiple osteochondromas, also known as
hereditary multiple exostoses [39]. A reduced level of EXT2 has
been found in exostosis chondrocytes [36–40]. Based on these
findings, EXT2 is discussed as a putative tumor suppressor.
Although these data contribute to understanding the biological
role of EXT2, they do not help to understanding the autoantibody
response that we frequently found in neuroblastoma. Antigens
may become immunogenic by fairly different mechanisms
including overexpression, mutation or aberrantly degradation.
Likewise post-translational modifications including glycosylation,
phosphorylation, oxidation or proteolytic cleavage may play a role
for proteins in becoming immunogenic by enhancing the self-
epitope or generating a neo-epitope [41].
For diagnostic purposes, our analysis focuses on the comparison
between neuroblastoma and Wilms tumors it is important to ask
whether the antigens that contribute best to this separation are also
frequently immunogenic in other tumor diseases. To this extend
we utilized data sets that we previously generated for various
tumors using the same technology and standard operating
procedures. Specifically, we considered immunogenic antigens
that were informative in the comparisons between glioma patients
and controls, lung cancer patients and controls and prostate
carcinoma patients and controls [27,29,32]. None of the clones
that were highly informative for the separation between neuro-
blastoma and Wilms tumor including the clones for exostosin-2,
ELAV-like protein 4, Microtubule-associated proteins 1A/1B light
chain 3A precursor and amyloid beta A4 precursor protein-
binding family B member 1 have been informative for any other
separation. Few clones that were less but yet informative for the
separation between neuroblastoma and Wilms tumor, were also
informative for other classifications: Nonhistone chromosomal
protein HMG-14 has also been informative for the classification
between prostate carcinoma and controls and vimentin was also
informative both for the classification between glioma and controls
and prostate carcinoma and controls (data not shown).
In summary we identified an autoantibody response in
neuroblastoma patients that showed a clearly increased number
of immunogenic informative antigens compared to Wilms tumor
patients. This is shown by the calculated AUC values for the
classification accuracy. An AUC value smaller than 0.3 for an
antigen means that this antigen reacted with significantly more
sera from neuroblastoma patients than with sera from Wilms
tumor patients whereas an AUC value higher than 0.7 for an
antigen means that this antigen reacted with significantly more
sera from Wilms tumor patients than with sera from neuroblas-
toma patients. As shown in Table 4 and 5, almost all antigens
informative for the classification were more reactive with sera from
neuroblastoma patients than with sera from Wilms tumor patients.
The identified autoantibody response allows to the separate
neuroblastoma from Wilms tumors with an accuracy of higher
than 85%. Since none of the informative antigens has previously
been reported as informative for other cancer patients, neuroblas-
toma appears to be a tumor with a rather specific and complex
autoantibody response. It is tempting to speculate whether this
response is related to the frequently observed spontaneous
remission without any chemotherapy.
Materials and Methods
Study population
Neuroblastoma blood samples. Neuroblastoma blood
samples were obtained with parents’ informed consent from the
Department of Pediatric Oncology and Hematology of the
Medical School of Cologne. Serum was isolated and
subsequently stored at 280uC. The study was approved by the
ethics committee of the University of the Cologne on the 9th of
September 2004 for the study NB 2004. We used 60 sera from 30
neuroblastoma patients (two sera from each patient, one prior to
and one after therapy). Sera from neuroblastoma patients have
been collected between 1992 and 2003. Clinical data of the
patients are shown in Figure S1.
Wilms tumor blood samples. Wilms tumor blood samples
were obtained from the multicenter study SIOP 2001/GPOH.
Serum was isolated and subsequently stored at 280uC. The study
was approved by the local ethics committee of the ‘‘A¨rztekammer
des Saarlandes’’ on September 2010 for nephroblastoma study
(No. 68/06). Patients or parents of minor patients gave their
written consent. We used 53 sera from Wilms tumor patients
prior to therapy and 35 sera of Wilms tumor patients after
therapy. Sera of Wilms tumor patients have been collected
between 2006 and 2009. Clinical data of the patients are shown
in Figure S2 and S3.
Protein macroarray screening
As previously described [29], we used a 1,827 clone array
(imaGenes, Berlin, Germany) for analysis, derived from a high-
density protein macroarray with 38,016 recombinant E.coli clones
of the hex1 library [42]. We screened this array with sera of
untreated and treated neuroblastoma patients and sera of
untreated and treated Wilms tumor patients.
Autoantibody Signature for Neuroblastoma
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The 1,827 clones array was washed twice in TBSTT (TBS,
0.05% Tween20, 0.5% Triton X-100) and four times in TBS.
Membranes were blocked with 3% non-fat dry milk in TBST
(TBS, 0.05% Tween20) and incubated over night with diluted sera
(1:1000). The sera were stored for a second round of incubation.
Membranes were washed with TBST and incubated with stripping
solution at 70uC. Membranes were washed twice with TBST and
four times with TBS and incubated in blocking solution for 2 h.
Membranes were once more incubated with serum overnight.
Membranes were washed with TBST and incubated with
secondary antibody (rabbit anti-human IgG, IgA, IgM-Cy5
(H+L), Dianova, Hamburg, Germany) (1:1000) for detection.
Membranes were washed four times with TBST, twice with TBS,
and dried overnight. Signal detection was carried out with a
Typhoon 9410 scanner (GE Healthcare, Uppsala, Sweden).
Image analysis
The spot intensity was evaluated by a fully automated image
analysis procedure as previously described [43]. The image
analysis of each filter resulted in an autoantibody profile consisting
of 3,654 integer intensity values ranging from 0 (no signal) to 255
(maximal intensity), corresponding to the 1,827 clones measured in
duplicates. The replicate values were averaged for all further
analyses. Not-available values were assigned to clones where no
appropriate spots could be detected. All 308 clones with more than
ten not-available values were excluded from further analysis.
Biostatistical analysis
To make the profiles from different arrays comparable to each
other, we performed a standard quantile normalization to
minimize array-to-array variations [43]. We used the remaining
1,520 clones for the classifications based on a linear kernel Support
Vector Machine (SVM) as described previously [44]. To
determine mean sensitivity, specificity and accuracy for the
classification tasks, we performed 20 repetitions of a standard
10-fold cross validation and, additionally, 20 classification runs
with randomly permuted class labels to test for overtraining. In
addition, we computed the 95% confidence intervals (95% CI) for
the classifications, the positive predicitive value (PPV) negative
predicitive value (NPV) as well as the positive and negative
likelihood ratios.
In order to determine the information content of single clones,
we calculated the area under the receiver -operating -characteristic
-curve (ROC) value (AUC value). The intensity values ranging
from 0 to 255 were considered to study the discrimination
potential of each seroreactive clone. For a given clone c and a
threshold h, we considered Wilms tumor sera as true positive (TP)
if clone c had an intensity value larger or equal h. If c had an
intensity value smaller than h, the Wilms tumor sera were typed as
false negative (FN). Neuroblastoma sera with intensity value above
the threshold were considered as false positive (FP), sera with
intensity values below the threshold were considered as true
negative (TN). To calculate the ROC curve and the AUC value of
the considered antigen, the sensitivity (TP/(TP+FN)) and speci-
ficity (TN/(TN+FP)) of varying thresholds were used. AUC values
of either 0 or 1 indicate a perfect separation. So, we considered
clones with AUC values below 0.3 and above 0.7 as informative
for a given separation task. We considered normalized intensity
values above 50 as positive seroreactivity to get binary information
for each clone, i.e., whether the clone is absent or present in a
sample.
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